all report title image
  • Published On : Aug 2022
  • Code : CMI2399
  • Industry : Pharmaceutical
  • Pages : 173
  • Formats :

Kidney cancer is a cancer that begins in the cells of kidneys. Kidney cancer is a cancer that begins in the kidneys. Kidneys are two bean-shaped organs, each about the size of fist. They're located behind abdominal organs, with one kidney on each side of spine. Renal cell carcinoma (RCC) is one of the most common types of kidney cancer in adults. At the advanced progression stage of kidney cancer, where removal of the cancerous cells is vital, surgical removal of kidney is performed to get cure from the disease. This treatment method has been replaced by laparoscopic removal of tumor-affected area. Medicines are generally prescribed to cure tumors at advanced stage of disease progression.

Global kidney cancer drugs market is estimated to be valued at US$ 5.83 billion in 2022 and is expected to exhibit a CAGR of 6.4% during the forecast period (2022-2030).

Figure 1. Global Kidney Cancer Drugs Market Share (%), by Pharmacologic Class, 2022

Kidney Cancer Drugs  | Coherent Market Insights

Increased prevalence of renal cell carcinoma is expected to drive the adoption of kidney cancer drugs during the forecast period.

Increasing prevalence of renal cell carcinoma is expected to drive the global kidney cancer drugs market over the forecast period. For instance, in February 2022, American Society of Clinical Oncology (ASCO), in 2022, an estimated 79,000 adults (50,290 men and 28,710 women) in the U.S. would be diagnosed with kidney cancer. Worldwide, an estimated 431,288 people were diagnosed with kidney cancer in 2020. In the U.S., kidney cancer is the sixth most common cancer for men. It is the ninth most common cancer for women. The average age at diagnosis for people with kidney cancer is 64, and most people are diagnosed between the ages of 65 and 74. Renal cell carcinoma (RCC) accounts for approximately 4% of all adult malignancies with nearly 270,000 new cases diagnosed annually worldwide in 2018 according to the National Center for Biotechnology Information.

CMI table icon

Kidney Cancer Drugs Market Report Coverage

Report Coverage Details
Base Year: 2021 Market Size in 2022: US$ 5.83 Bn
Historical Data for: 2017 to 2020 Forecast Period: 2022 to 2030
Forecast Period 2022 to 2030 CAGR: 6.4% 2030 Value Projection: US$ 9.60 Bn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Therapy: Targeted Therapy, Immunotherapy, Chemotherapy
  • By Pharmacological Class: Angiogenesis Inhibitors, mTOR Inhibitors, Cytokines, Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 
Companies covered:

Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.

Growth Drivers:
  • Increased prevalence of renal cell carcinoma
  • Combination immunotherapy strategies are increasing trend for the treatment of patient suffering with kidney cancer
Restraints & Challenges:
  • Increasing use of targeted therapies and biologics for the treatment of kidney cancer

Figure 2. Global Kidney Cancer Drugs Market Share (%), by Region, 2022

Kidney Cancer Drugs  | Coherent Market Insights

Combination immunotherapy strategies are increasing trend for the treatment of patient suffering with kidney cancer, which offer lucrative growth opportunities for the market over the forecast period.

In recent times, combination immunotherapy strategies are increasing trend for the treatment of patient suffering with kidney cancer, which offer lucrative growth opportunities  for the market over the forecast period. For instance, in December 2017, the U.S. Food and Drug administration granted Breakthrough Therapy designation to avelumab, PD-L1 immune checkpoint inhibitor, and axitinib, anti-VEGF tyrosine kinase inhibitor (TKI), as a combination therapy for treatment-naive patients with advanced Renal Cell Carcinoma. Furthermore, in January 2018, U.S. Food and Drug administration granted the same designation to, lenvatinib mesylate, multi-TKI, and pembrolizumab, PD-1 immune checkpoint inhibitor, as another combination for mRCC. Moreover, the field of initial treatment therapy for metastatic renal cell carcinoma is moving rapidly towards combination therapy.

Global Kidney Cancer Drugs Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization had declared it a public health emergency on January 30, 2020.

COVID-19 can affect the economy in three main ways: by directly affecting production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries, such as China, India, Saudi Arabia, U.A.E., Egypt, and others, are facing problems with regards to the transportation of drugs from one place to another.

However, the COVID-19 pandemic had a negative impact on the global kidney cancer drugs market, owing to the decrease in research and development activities for kidney cancer drugs. For instance, in May 2020, according to data published by the National Center for Biotechnology Information, the clinicians were focused on developing the SARS-CoV-2 vaccine to prevent the rapid spread of the coronavirus in the world. The coronavirus disease 2019 (COVID-19) was spreading globally at an alarming rate due to which government of countries announced lockdown all over the world.  Capacity for surgery has also been reduced as theater space and ventilators have been requisitioned to provide additional critical care capacity for patients with COVID-19. Moreover, anecdotal reports of patients developing COVID-19 after admission to hospital for elective surgery had resulted in patients being more reluctant to have surgery. Thus, as large number of researchers and clinicians were concentrated on developing covid-19 vaccine, the research and development activities for the kidney cancer drugs were decreased.

Global Kidney Cancer Drugs Market: Key Developments

In January 2022, Clinical Hospital of the Faculty of Medicine of Ribeirão Preto collaborated with Bristol Myers Squibb (pharmaceutical company) and São Paulo Research Foundation for developing Nivolumab- new drug on renal cancer. Nivolumab is in the Phase 2 clinical trial whose study was started in January 18 2022. The primary completion date is estimated to be November 30, 2024.

Global Kidney Cancer Drugs Market: Restraint

The major factors that hinder growth of the global kidney cancer drugs market include increasing use of targeted therapies and biologics for treatment of kidney cancer. Targeted therapies are used to control cancer cell when kidney cancer is spread to other organs where chemical drugs are ineffective. Also, targeted therapies for kidney cancer has illustrated higher efficiency than normal chemical drug-based chemotherapy in random clinical trials.

Key Players

Major players operating in the global kidney cancer drugs market include Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.

Kidney cancer or renal carcinoma affects kidney cells to grow out of control and restrict the function of normal cells. Several risk factors associated with kidney cancer include smoking, obesity, workplace exposures substances such as cadmium, some herbicides, and organic solvents, particularly trichloroethylene, high blood pressure, advanced kidney disease, certain medicines, and genetic and hereditary risk factors. Clear cell renal cell carcinoma is the most common form of renal cell carcinoma. When seen in the lab, the cells that make up clear cell Renal Cell Carcinoma look very pale or clear. Increasing exposure of these risk factors offers lucrative growth outlook in the kidney cancer drugs market, over the forecast period. According to American Cancer Society, January 2018 data findings, kidney cancer was among the 10 most common cancers in the U.S. in both men and women. Men had a higher risk of developing kidney cancer, with about 1 in 48 men and 1 in 83 among women facing lifetime risk of developing kidney cancer. Renal cell carcinoma (RCC) was the most common type of kidney cancer among all types of kidney cancer. In addition, according to same source, around 9 out of 10 kidney cancers were renal cell carcinomas.

Market Dynamics

Key players are engaged in developing cancer immunotherapy drugs to fight cancer and improve immune system. For instance, in January 2019, F. Hoffmann-La Roche Ltd., a healthcare company was working on Tecentriq (atezolizumab, anti-PDL1, RG7446, MPDL3280A), an engineered monoclonal antibody, that targets the ligand PD-L1 (programmed death ligand 1) aiming to prevent cancer immune evasion, which would be used as adjuvant treatment in renal cell carcinoma treatment. Tecentriq is in phase III stage.

Key features of the study:

  • This report provides an in-depth analysis of the global kidney cancer drugs market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global kidney cancer drugs market  based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Pfizer Inc., Novartis International AG, Genentech, Inc.,  Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global kidney cancer drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts1
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global kidney cancer drugs market

Detailed Segmentation:

  • Global Kidney Cancer Drugs Market, By Therapy:
    • Targeted Therapy
    • Immunotherapy
    • Chemotherapy
  • Global Kidney Cancer Drugs Market, By Pharmacological Class:
    • Angiogenesis Inhibitors
    • mTOR Inhibitors
    • Cytokines
    • Others (Immune checkpoint inhibitors, CTLA-4 inhibitors, antimetabolites and others)
  • Global Kidney Cancer Drugs Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies 
    • Online Pharmacies
  • Global Kidney Cancer Drugs Market, By Region:
    • North America
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Region/Country
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Pfizer Inc.*
      • Company Highlights
      • Products Portfolio
      • Key Highlights
      • Financial Performance
      • Strategies
    • Novartis International AG
    • Genentech, Inc.
    • Active Biotech AB
    • Amgen Inc.
    • Bayer AG
    • Cipla Limited
    • Hoffmann-La Roche AG
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Exelixis, Inc.

“*” marked represents similar segmentation in other categories in the respective section.

Frequently Asked Questions

The global kidney cancer drugs market size is estimated to be valued at US$ 5.83 billion in 2022 and is expected to exhibit a CAGR of 6.4% between 2022 and 2030.
Factors such as increased prevalence of renal cell carcinoma and combination immunotherapy strategies are increasing trend for the treatment of patient suffering with kidney cancer are expected to drive the market growth.
Angiogenesis inhibitors is the leading pharmacologic class segment in the market. 
The major factors hampering growth of the market include increasing use of targeted therapies and biologics for treatment of kidney cancer.
Major players operating in the market include Pfizer Inc., Novartis International AG, Genentech, Inc., Active Biotech AB, Amgen Inc., Bayer AG, Cipla Limited, Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Eisai Co., Ltd., and Exelixis, Inc.

Related Reports

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo